[1]董震宇 穆耶赛尔·玉苏普 芦颜美 汤宝鹏.介入器械治疗慢性心力衰竭的研究进展[J].心血管病学进展,2023,(12):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]
　DONG Zhenyu,Muyassar·Yusup,LU Yanmei,et al.Device-based Interventional Strategies for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(12):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]
点击复制

介入器械治疗慢性心力衰竭的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年12期
页码:
1061
栏目:
综述
出版日期:
2023-12-25

文章信息/Info

Title:
Device-based Interventional Strategies for Chronic Heart Failure
作者:
董震宇 穆耶赛尔·玉苏普 芦颜美 汤宝鹏
(新疆医科大学第一附属医院心脏中心起搏电生理科新疆心电生理与心脏重塑重点实验室,新疆 乌鲁木齐 830000)
Author(s):
DONG Zhenyu; Muyassar·Yusup; LU Yanmei; TANG Baopeng
(Department of Pacing and Electrophysiology Department of Cardiac Electrophysiology and Remodeling,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,Xinjiang,China)
关键词:
心力衰竭; 介入治疗; 器械治疗
Keywords:
Heart failure; Interventional strategy; Instrumental Therapy
DOI:
10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002
摘要:
现总结了在慢性心力衰竭治疗领域介入器械的研究进展，主要包括辅助心脏自身收缩能力的设备，减少心脏做功负荷的器械和间接调节心脏的装置。慢性心力衰竭介入领域近来涌现出多种新型介入手段，分别作用于心力衰竭的各个病理途径。目前已经开展了大量与之相关的临床前和临床研究。现有的临床研究证据已经证明了多种介入器械对慢性心力衰竭患者在生活质量和运动能力方面的改善，但较少有证据证明心力衰竭介入器械在住院率和死亡率的改善。
Abstract:
This review provides a comprehensive overview of recent advances in interventional devices for the treatment of chronic heart failure. These devices primarily include those that assist the heart’s intrinsic contractile capacity, reduce cardiac workload, and indirectly modulate cardiac function. In the field of chronic heart failure intervention, a variety of novel approaches have emerged, targeting different pathological pathways of heart failure. A substantial body of preclinical and clinical research has been undertaken in this context. Existing clinical research evidence has demonstrated the improvement in quality of life and exercise capacity in chronic heart failure patients with various interventional devices. However, there is limited evidence to suggest improvements in hospitalization rates and mortality

参考文献/References:

[1] Bragazzi NL,Zhong W,Shu J,et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017[J]. Eur J Prev Cardiol,2021,28(15):1682-1690.

[2] Hao G,Wang X,Chen Z,et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey,2012-2015[J]. Eur J Heart Fail,2019,21(11):1329-1337.

[3] 华伟,顾敏,宿燕岗,等. 中国慢性心力衰竭患者中左心室多位点起搏有效性和安全性的观察和评价[J]. 中华心律失常学杂志,2022,26(2):152-158.

[4] Mehta VS,Elliott MK,Sidhu BS,et al. Multipoint pacing for cardiac resynchronisation therapy in patients with heart failure:a systematic review and meta-analysis[J]. J Cardiovasc Electrophysiol,2021,32(9):2577-2589.

[5] Upadhyay GA,Vijayaraman P,Nayak HM,et al. On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization:a secondary analysis of the His-SYNC pilot trial[J]. Heart Rhythm,2019,16(12):1797-1807.

[6] Seyfarth M,Sibbing D,Bauer I,et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction[J]. J Am Coll Cardiol,2008,52(19):1584-1588.

[7] Aragon J,Lee MS,Kar S,et al. Percutaneous left ventricular assist device:“TandemHeart” for high-risk coronary intervention[J]. Catheter Cardiovasc Interv,2005,65(3):346-352.

[8] Estep JD,Starling RC,Horstmanshof DA,et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients:results from the ROADMAP study[J]. J Am Coll Cardiol,2015,66(16):1747-1761.

[9] Zhang J,Chen Z,Griffith BP,et al. Computational characterization of flow and blood damage potential of the new maglev CH-VAD pump versus the HVAD and HeartMateⅡpumps[J]. Int J Artif Organs,2020,43(10):653-662.

[10] Naar J ,Skalsk? I,Kr?ger A,et al. Long-term results of hybrid left ventricular reconstruction in the treatment of ischemic cardiomyopathy[J]. J Cardiovasc Transl Res,2021,14(6):1043-1050.

[11] Mann DL,Lee RJ,Coats AJ,et al. One-year follow-up results from AUGMENT-HF:a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure[J]. Eur J Heart Fail,2016,18(3):314-325.

[12] Imai M,Rastogi S,Gupta RC,et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure[J]. J Am Coll Cardiol,2007,49(21):2120-2128.

[13] 董震宇,芦颜美,李耀东,等. 心肌收缩力调节器对心力衰竭患者有效性的荟萃分析[J]. 中华心律失常学杂志,2022,26(6):534-539.

[14] Schau T,Seifert M,Meyh?fer J,et al. Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure[J]. Europace,2011,13(10):1436-1444.

[15] Griffin JM,Borlaug BA,Komtebedde J,et al. Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure[J]. J Am Heart Assoc,2020,9(17):e016760.

[16] Del Trigo M,Bergeron S,Bernier M,et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-of-principle cohort study[J]. Lancet,2016,387(10025):1290-1297.

[17] Rodés-Cabau J,Bernier M,Amat-Santos IJ,et al. Interatrial shunting for heart failure:early and late results from the first-in-human experience with the V-Wave system[J]. JACC Cardiovasc Interv,2018,11(22):2300-2310.

[18] Shang X,Liu M,Zhong Y,et al. Clinical study on the treatment of chronic heart failure with a novel D-shant atrium shunt device[J]. ESC Heart Fail,2022,9(3):1713-1720.

[19] Shah SJ,Borlaug BA,Chung ES,et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HFⅡ):a randomised,multicentre,blinded,sham-controlled trial[J]. Lancet,2022,399(10330):1130-1140.

[20] Annamalai SK,Esposito ML,Reyelt LA,et al. Abdominal positioning of the next-generation intra-aortic fluid entrainment pump (Aortix) improves cardiac output in a swine model of heart failure[J]. Circ Heart Fail,2018,11(8):e005115.

[21] Vora AN,Schuyler Jones W,DeVore AD,et al. First-in-human experience with Aortix intraaortic pump[J]. Catheter Cardiovasc Interv,2019,93(3):428-433.

[22] Rosenblum H,Kapur NK,Abraham WT,et al. Conceptual considerations for device-based therapy in acute decompensated heart failure:DRI2P2S[J]. Circ Heart Fail,2020,13(4):e006731.

[23] Kapur NK,Reyelt L,Crowley P,et al. Intermittent occlusion of the superior vena cava reduces cardiac filling pressures in preclinical models of heart failure[J]. J Cardiovasc Transl Res,2020,13(2):151-157.

[24] Dierckx R,Vanderheyden M,Heggermont W,et al. Treatment of diuretic resistance with a novel percutaneous blood flow regulator:concept and initial experience[J]. J Card Fail,2019,25(11):932-934.

[25] Abraham WT,Adamson PB,Bourge RC,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure:a randomised controlled trial[J]. Lancet,2011,377(9766):658-666.

[26] Mullens W,Sharif F,Dupont M,et al. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System:results of the SIRONA first-in-human study[J]. Eur J Heart Fail,2020,22(10):1912-1919.

[27] Gold MR,van Veldhuisen DJ,Hauptman PJ,et al. Vagus nerve stimulation for the treatment of heart failure:the INOVATE-HF trial[J]. J Am Coll Cardiol,2016,68(2):149-158.

[28] Sant’Anna LB,Couceiro SLM,Ferreira EA,et al. Vagal neuromodulation in chronic heart failure with reduced ejection fraction:a systematic review and meta-analysis[J]. Front Cardiovasc Med,2021,8:766676.

[29] Zile MR,Lindenfeld J,Weaver FA,et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction[J]. J Am Coll Cardiol,2020,76(1):1-13.

[30] Zhang Y,Gao C,Greene SJ,et al. Clinical performance and quality measures for heart failure management in China:the China-Heart Failure registry study[J]. ESC Heart Fail,2023,10(1):342-352.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(12):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(12):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(12):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(12):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(12):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2024-01-19